Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Want An RMAT Designation? Please Include At Least Some Data, US FDA Tells Sponsors

Executive Summary

CBER's Rachael Anatol says such a situation has happened "more than a few times"; instances appear to have been largely concentrated in earlier days of the RMAT program.

Advertisement

Related Content

RMAT Designation Requests May Rise Or Fall On Manufacturing Changes, Clinical Data Breadth
Regenerative Medicine Clinical Trials: US FDA Supports Studies Comparing Multiple Agents
Why Most Regenerative Therapy Applications for US RMAT Designation Fail to Make The Grade

Topics

Advertisement
UsernamePublicRestriction

Register

PS124035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel